10,631 reports of this reaction
4.7% of all VEDOLIZUMAB reports
#3 most reported adverse reaction
CROHN^S DISEASE is the #3 most commonly reported adverse reaction for VEDOLIZUMAB, manufactured by Takeda Pharmaceuticals America, Inc.. There are 10,631 FDA adverse event reports linking VEDOLIZUMAB to CROHN^S DISEASE. This represents approximately 4.7% of all 224,197 adverse event reports for this drug.
VEDOLIZUMAB has an overall safety score of 88 out of 100. Patients taking VEDOLIZUMAB who experience crohn^s disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CROHN^S DISEASE is moderately reported among VEDOLIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to crohn^s disease, the following adverse reactions have been reported for VEDOLIZUMAB:
The following drugs have also been linked to crohn^s disease in FDA adverse event reports:
CROHN^S DISEASE has been reported as an adverse event in 10,631 FDA reports for VEDOLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CROHN^S DISEASE accounts for approximately 4.7% of all adverse event reports for VEDOLIZUMAB, making it one of the most commonly reported side effect.
If you experience crohn^s disease while taking VEDOLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.